Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2021 | Colorectal Cancer | Research

Targeting the hallmarks of cancer: the effects of silibinin on proliferation, cell death, angiogenesis, and migration in colorectal cancer

Authors: Saba Sameri, Chiman Mohammadi, Mehrnaz Mehrabani, Rezvan Najafi

Published in: BMC Complementary Medicine and Therapies | Issue 1/2021

Abstract

Background

Silibinin, as a chemopreventive agent, has shown anti-cancer efficacy against different types of cancers. In the present study, we investigated the anti-cancer activities of silibinin on CT26 mouse colon cell line.

Methods

CT26 cells were treated with different concentrations of silibinin. To examine the cytotoxic effect of silibinin on proliferation, apoptosis, autophagy, angiogenesis, and migration, MTT, colony-forming assay, Annexin V/PI flow cytometry, RT-qPCR, and Scratch assay were used.

Results

Silibinin was found to significantly reduce CT26 cells survival. Furthermore, silibinin strongly induced apoptosis and autophagy by up-regulating the expression of Bax, Caspase-3, Atg5, Atg7 and BECN1 and down-regulating Bcl-2. Silibinin considerably down-regulated the expression of COX-2, HIF-1α, VEGF, Ang-2, and Ang-4 as well as the expression of MMP-2, MMP-9, CCR-2 and CXCR-4.

Conclusions

The present study revealed that silibinin shows anticancer activities by targeting proliferation, cell survival, angiogenesis, and migration of CT26 cells.

Hanahan D. Weinberg RA. Hallmarks of cancer: the next generation cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703–19. https://doi.org/10.4161/rna.20481.CrossRefPubMedPubMedCentral

Folkman J. Angiogenesis. Annu Rev Med. 2006;57(1):1–18. https://doi.org/10.1146/annurev.med.57.121304.131306.CrossRefPubMed

Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C, et al. Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther. 2009;8(8):2366–74. https://doi.org/10.1158/1535-7163.MCT-09-0304.CrossRefPubMedPubMedCentral

Prasad NR, Muthusamy G, Shanmugam M, Ambudkar SV. South Asian medicinal compounds as modulators of resistance to chemotherapy and radiotherapy. Cancers. 2016;8(3):32. https://doi.org/10.3390/cancers8030032.CrossRefPubMedCentral

Montgomery A, Adeyeni T, San K, Heuertz RM, Ezekiel UR. Curcumin sensitizes silymarin to exert synergistic anticancer activity in colon cancer cells. J Cancer. 2016;7(10):1250–7. https://doi.org/10.7150/jca.15690.CrossRefPubMedPubMedCentral

Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res. 2002;62(11):3063–9.PubMed

Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, et al. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst. 2006;98(12):846–55. https://doi.org/10.1093/jnci/djj231.CrossRefPubMed

Gu M, Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res. 2007;67(7):3483–91. https://doi.org/10.1158/0008-5472.CAN-06-3955.CrossRefPubMed

10.

Half E, Arber N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother. 2009;10(2):211–9. https://doi.org/10.1517/14656560802560153.CrossRefPubMed

11.

Balachandran C, Sangeetha B, Duraipandiyan V, Raj MK, Ignacimuthu S, Al-Dhabi N, et al. A flavonoid isolated from Streptomyces sp.(ERINLG-4) induces apoptosis in human lung cancer A549 cells through p53 and cytochrome c release caspase dependant pathway. Chem Biol Interact. 2014;224:24–35. https://doi.org/10.1016/j.cbi.2014.09.019.CrossRefPubMed

12.

Olaru OT, Venables L, Van De Venter M, Nitulescu GM, Margina D, Spandidos DA, et al. Anticancer potential of selected Fallopia Adans species. Oncol Lett. 2015;10(3):1323–32. https://doi.org/10.3892/ol.2015.3453.CrossRefPubMedPubMedCentral

13.

Kwan YP, Saito T, Ibrahim D, Al-Hassan FMS, Ein Oon C, Chen Y, et al. Evaluation of the cytotoxicity, cell-cycle arrest, and apoptotic induction by Euphorbia hirta in MCF-7 breast cancer cells. Pharm Biol. 2016;54(7):1223–36. https://doi.org/10.3109/13880209.2015.1064451.CrossRefPubMed

14.

Moradi M, Najafi R, Amini R, Solgi R, Tanzadehpanah H, Esfahani AM, et al. Remarkable apoptotic pathway of hemiscorpius lepturus scorpion venom on CT26 cell line. Cell Biol Toxicol. 2019;35(4):373–85. https://doi.org/10.1007/s10565-018-09455-3.CrossRefPubMed

15.

Sameri S, Saidijam M, Bahreini F, Najafi R. Cancer chemopreventive activities of silibinin on colorectal cancer through regulation of E-cadherin/β-catenin pathway. Nutr Cancer. 2020:1–11. https://doi.org/10.1080/01635581.

16.

Bai Z-L, Tay V, Guo S-Z, Ren J, Shu M-G. Silibinin induced human glioblastoma cell apoptosis concomitant with autophagy through simultaneous inhibition of mTOR and YAP. Biomed Res Int. 2018;2018:1–10. https://doi.org/10.1155/2018/6165192.CrossRef

17.

Zheng N, Liu L. Liu W-w, Li F, Hayashi T, Tashiro S-i, et al. crosstalk of ROS/RNS and autophagy in silibinin-induced apoptosis of MCF-7 human breast cancer cells in vitro. Acta Pharmacol Sin. 2017;38(2):277–89. https://doi.org/10.1038/aps.2016.117.CrossRefPubMed

18.

Jahanafrooz Z, Motamed N, Rinner B, Mokhtarzadeh A, Baradaran B. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life Sci. 2018;213:236–47. https://doi.org/10.1016/j.lfs.2018.10.009.CrossRefPubMed

19.

Mathonnet M, Perraud A, Christou N, Akil H, Melin C, Battu S, et al. Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells. World J Gastroenterol: WJG. 2014;20(15):4189–96. https://doi.org/10.3748/wjg.v20.i15.4189.CrossRefPubMed

20.

Thorburn A. Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis. 2008;13(1):1–9. https://doi.org/10.1007/s10495-007-0154-9.CrossRefPubMedPubMedCentral

21.

Raina K, Agarwal C, Wadhwa R, Serkova NJ, Agarwal R. Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries. Autophagy. 2013;9(5):697–713. https://doi.org/10.4161/auto.23960.CrossRefPubMedPubMedCentral

22.

Tyagi A, Singh RP, Agarwal C, Agarwal R. Silibinin activates p53-caspase 2 pathway and causes caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: evidence for a regulatory loop between p53 and caspase 2. Carcinogenesis. 2006;27(11):2269–80. https://doi.org/10.1093/carcin/bgl098.CrossRefPubMed

23.

Fan S, Qi M, Yu Y, Li L, Yao G, Tashiro S-I, et al. P53 activation plays a crucial role in silibinin induced ROS generation via PUMA and JNK. Free Radic Res. 2012;46(3):310–9. https://doi.org/10.3109/10715762.2012.655244.CrossRefPubMed

24.

Zhang X, Liu J, Zhang P, Dai L, Wu Z, Wang L, et al. Silibinin induces G1 arrest, apoptosis and JNK/SAPK upregulation in SW1990 human pancreatic cancer cells. Oncol Lett. 2018;15(6):9868–76. https://doi.org/10.3892/ol.2018.8541.CrossRefPubMedPubMedCentral

25.

Bayram D, Çetin E, Kara M, Özgöçmen M, Candan I. The apoptotic effects of silibinin on MDA-MB-231 and MCF-7 human breast carcinoma cells. Human & experimental toxicology. 2017;36(6):573–86. https://doi.org/10.1177/0960327116658105.CrossRef

26.

Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI–CDK–cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis. 2004;25(9):1711–20. https://doi.org/10.1093/carcin/bgh180.CrossRefPubMed

27.

Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402(6762):672–6. https://doi.org/10.1038/45257.CrossRefPubMed

28.

Yuan J, Lipinski M, Degterev A. Diversity in the mechanisms of neuronal cell death. Neuron. 2003;40(2):401–13. https://doi.org/10.1016/S0896-6273(03)00601-9.CrossRefPubMed

29.

Kondo Y, Kondo S. Autophagy and cancer therapy. Autophagy. 2006;2(2):85–90. https://doi.org/10.4161/auto.2.2.2463.CrossRefPubMed

30.

Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci. 2004;117(13):2805–12. https://doi.org/10.1242/jcs.01131.CrossRefPubMed

31.

Rybstein MD, Bravo-San Pedro JM, Kroemer G, Galluzzi L. The autophagic network and cancer. Nat Cell Biol. 2018;20(3):243–51. https://doi.org/10.1038/s41556-018-0042-2.CrossRefPubMed

32.

Duan W, Jin X, Li Q. Tashiro S-i, Onodera S, Ikejima T. Silibinin induced autophagic and apoptotic cell death in HT1080 cells through a reactive oxygen species pathway. J Pharmacol Sci. 2010;113(1):48–56. https://doi.org/10.1254/jphs.09315FP.CrossRefPubMed

33.

Lv X, Li J, Zhang C, Hu T, Li S, He S, et al. The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism. Genes & diseases. 2017;4(1):19–24. https://doi.org/10.1016/j.gendis.2016.11.003.CrossRef

34.

López-Lázaro M. Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. Cancer Epidemiol Prev Biomarkers. 2006;15(12):2332–5. https://doi.org/10.1158/1055-9965.EPI-06-0369.CrossRef

35.

Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 2008;68(6):2043–50. https://doi.org/10.1158/0008-5472.CAN-07-6247.CrossRefPubMed

36.

Kim S, Kim SH, Hur SM, Lee S-K, Kim WW, Kim JS, et al. Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells. J Ethnopharmacol. 2009;126(2):252–7. https://doi.org/10.1016/j.jep.2009.08.032.CrossRefPubMed

37.

Fukuda R, Hirota K, Fan F, Do Jung Y, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002;277(41):38205–11. https://doi.org/10.1074/jbc.M203781200.CrossRefPubMed

38.

Chen P-N, Hsieh Y-S, Chiou H-L, Chu S-C. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact. 2005;156(2–3):141–50. https://doi.org/10.1016/j.cbi.2005.08.005.CrossRefPubMed

39.

Yamakawa M, Liu LX, Belanger AJ, Date T, Kuriyama T, Goldberg MA, et al. Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis. A J Physiol-Renal Physiol. 2004;287(4):F649–F57. https://doi.org/10.1152/ajprenal.00028.2004.CrossRef

40.

Simon MP, Tournaire R, Pouyssegur J. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J Cell Physiol. 2008;217(3):809–18. https://doi.org/10.1002/jcp.21558.CrossRefPubMed

41.

Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY, et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res. 2003;93(7):664–73. https://doi.org/10.1161/01.RES.0000093984.48643.D7.CrossRefPubMed

42.

Kurzejamska E, Sacharczuk M, Landázuri N, Kovtonyuk O, Lazarczyk M, Ananthaseshan S, et al. Effect of chemokine (CC motif) ligand 7 (CCL7) and its receptor (CCR2) expression on colorectal Cancer behaviors. Int J Mol Sci. 2019;20(3):686. https://doi.org/10.3390/ijms20030686.CrossRefPubMedCentral

43.

Forghani P, Khorramizadeh MR, Waller EK. Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast Cancer. Cancer med. 2014;3(2):215–24. https://doi.org/10.1002/cam4.186.CrossRefPubMedPubMedCentral

44.

Oh YS, Kim HY, Song I-C, Yun H-J, Jo D-Y, Kim S, et al. Hypoxia induces CXCR4 expression and biological activity in gastric cancer cells through activation of hypoxia-inducible factor-1α. Oncol Rep. 2012;28(6):2239–46. https://doi.org/10.3892/or.2012.2063.CrossRefPubMed

45.

Wang Y, Liang W-C, Pan W-L, Law W-K, Hu J-S, Ip DT-M, et al. Silibinin, a novel chemokine receptor type 4 antagonist, inhibits chemokine ligand 12-induced migration in breast cancer cells. Phytomedicine. 2014;21(11):1310–7. https://doi.org/10.1016/j.phymed.2014.06.018.CrossRefPubMed

46.

Webb AH, Gao BT, Goldsmith ZK, Irvine AS, Saleh N, Lee RP, et al. Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 2017;17(1):434. https://doi.org/10.1186/s12885-017-3418-y.CrossRefPubMedPubMedCentral

47.

Tang C-H, Tan T-W, Fu W-M, Yang R-S. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis. 2008;29(1):35–43. https://doi.org/10.1093/carcin/bgm220.CrossRefPubMed

48.

Zhang R, Pan X, Huang Z, Weber GF, Zhang G. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One. 2011;6(8):e23831. https://doi.org/10.1371/journal.pone.0023831.

49.

Byun HJ, Darvin P, Kang DY, Sp N, Joung YH, Park JH, et al. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells. Oncol Rep. 2017;37(6):3270–8. https://doi.org/10.3892/or.2017.5588.CrossRefPubMed

50.

Oh S-J, Jung SP, Han J, Kim S, Kim JS, Nam SJ, et al. Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells. Oncol Rep. 2013;29(4):1343–8. https://doi.org/10.3892/or.2013.2252.CrossRefPubMed

Title: Targeting the hallmarks of cancer: the effects of silibinin on proliferation, cell death, angiogenesis, and migration in colorectal cancer
Authors: Saba Sameri
Chiman Mohammadi
Mehrnaz Mehrabani
Rezvan Najafi
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: BMC Complementary Medicine and Therapies / Issue 1/2021
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-021-03330-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Targeting the hallmarks of cancer: the effects of silibinin on proliferation, cell death, angiogenesis, and migration in colorectal cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

The effect of the Verbascum Thapsus on episiotomy wound healing in nulliparous women: a randomized controlled trial

Traditional medicine among the community of Gash-Barka region, Eritrea: attitude, societal dependence, and pattern of use

Up-regulation of long non-coding RNA CYTOR induced by icariin promotes the viability and inhibits the apoptosis of chondrocytes

Effects of a new thyrotropic drug isolated from Potentilla alba on the male reproductive system of rats and offspring development

Identification of 3,3′-O-dimethylellagic acid and apigenin as the main antiplasmodial constituents of Endodesmia calophylloides Benth and Hymenostegia afzelii (Oliver.) Harms

Tetrandrine alleviates podocyte injury via calcium-dependent calpain-1 signaling blockade